Assembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $15.65 and traded as high as $17.68. Assembly Biosciences shares last traded at $17.37, with a volume of 23,726 shares.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ASMB shares. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a report on Friday, December 27th. Jefferies Financial Group upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and increased their price target for the company from $2.00 to $35.00 in a research note on Friday, September 20th.

Assembly Biosciences Trading Up 0.1 %

The firm has a fifty day simple moving average of $16.03 and a 200-day simple moving average of $15.65.

Insider Transactions at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was bought at an average cost of $15.61 per share, with a total value of $49,983.22. Following the transaction, the director now owns 3,202 shares of the company’s stock, valued at $49,983.22. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

Several large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 3,442 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 7,690 shares in the last quarter. FMR LLC increased its stake in shares of Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 3,635 shares during the period. Renaissance Technologies LLC raised its holdings in Assembly Biosciences by 39.2% during the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares in the last quarter. Finally, Armistice Capital LLC acquired a new stake in Assembly Biosciences in the second quarter valued at about $6,421,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.